Steatohepatitis/Metabolic Liver Disease News

Fibrosis-4 index followed by measurement of liver stiffness with vibration-controlled transient elastography or Enhanced Liver Fibrosis test maintained acceptable noninvasive performance in identifying advanced fibrosis due to nonalcoholic steatohepatitis while reducing the rate of indeterminate results, according to an analysis of the STELLAR trial outcomes.

DILIsym Services released NAFLDsym Version 2A, a quantitative systems pharmacology modeling software designed to support the development of treatments for nonalcoholic fatty liver disease, according to a press release.

Boehringer Ingelheim and Yuhan Corporation announced a collaboration and license agreement to development a combination of GLP-1 and FGF21 activity into one molecule for treating nonalcoholic steatohepatitis and related liver diseases, according to a press release.

Zydus Cadila completed patient enrollment in its phase 2 trial of Lipaglyn for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release.

Emricasan did not meet its either of its primary phase 2b trial endpoints in patients with nonalcoholic steatohepatitis-related decompensated cirrhosis, according to a press release from Conatus Pharmaceuticals. The company also stated that it is discontinuing further treatment of enrolled patients.

High Point Clinical Trials Center announced a 3-year collaboration with ProSciento to join NASH PASS as a site partner, according to a press release.

As liver health advocates continue seeking opportunities to increase public awareness about liver diseases, the Global Liver Institute declared nonalcoholic steatohepatitis a “hidden epidemic” as they led this year’s International NASH Day.

Interim data from an ongoing phase 2b trial of CymaBay’s seladelpar as a treatment for nonalcoholic steatohepatitis showed that the PPAR agonist did not reduce hepatic fat compared with placebo, but did show significant reductions in transaminase levels, according to Sujal Shah, president and CEO of the company.

This year’s International NASH Day, led by the Global Liver Institute, is focused on the anticipated rise of nonalcoholic steatohepatitis in years to come and experts have highlighted key strategic issues to improve clinical management and health system preparedness from a policy perspective.

In this guest editorial, Joel E. Lavine, MD, PhD, chief of pediatric gastroenterology, hepatology, and nutrition at th e Columbia College of Physicians and Surgeons , discusses the future of treating nonalcoholic fatty liver disease and its progressive form, nonalcoholic steatohepatitis, as these epidemics accompany with increasing obesity prevalence . He explains that even with upcoming therapeutics and noninvasive screening methods, appropriate diet and exercise are vital to avoiding and treating these diseases.